Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02131324 · ClinicalTrials.gov registry record · Phase 2
DFD06 Cream vs Clobetasol Propionate Cream, 0.05% Hypothalamic- Pituitary-Adrenal (HPA) Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis
A Phase 2 study, sponsored by Promius Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT02131324 is a Phase 2 study that has completed, run by Promius Pharma. The registered enrollment target is 50 participants.
The verdict
NCT02131324, a Phase 2 study, has completed, sponsored by Promius Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the potential of DFD06 cream to suppress the HPA (hypothalamic-pituitary-adrenal) axis as compared to clobetasol propionate cream, 0.05% cream when applied twice daily for 15 days.
Interventions
- DRUG DFD06 Cream
- DRUG Clobetasol Propionate Cream 0.05%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2014-05-08 |
| Est. Completion | 2016-08-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02131324
The ClinicalTrials.gov registry entry for NCT02131324 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Promius Pharma, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which DFD06 Cream is the first listed.
NCT02131324 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02131324 about?
NCT02131324 is a clinical study titled "DFD06 Cream vs Clobetasol Propionate Cream, 0.05% Hypothalamic- Pituitary-Adrenal (HPA) Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis". The purpose of this study is to evaluate the potential of DFD06 cream to suppress the HPA (hypothalamic-pituitary-adrenal) axis as compared to clobetasol propionate cream, 0.05% cream when applied twice daily for 15 days.
What is the current status of trial NCT02131324?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2014-05-08. Estimated completion is 2016-08-11.
What interventions are being tested in trial NCT02131324?
The interventions under investigation include: DFD06 Cream (DRUG), Clobetasol Propionate Cream 0.05% (DRUG).
Who is sponsoring clinical trial NCT02131324?
This trial is sponsored by Promius Pharma, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.